Table 1 Prognostic biomarkers in chronic lymphocytic leukemia
From: Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia
Category | Prognostic biomarkers |
|---|---|
Serum markers | Thymidine kinase, beta2-microglobulin, lactic dehydrogenase, lymphocyte doubling time, autocrine interleukin-6, copper, free light chains, lipoprotein lipase, c-reaction protein, BAFF, TACI, APRIL, BCMA, EZH2 |
Immunophenotypic markers | CD38, ZAP70, CD49d, CD26, CD54, CD44, CD52, CD69, CD25, CD5, CD95, CD39, CD11c, CD36, CD150 |
IGHV mutation status | M-CLL, U-CLL |
Chromosome aberrations | Del13q, del11q, tri12, del17p, del16q, del19p21, del10q23, total or partial trisomies of chromosomes 3, 8, 18, 19 and duplications in 2p24 |
Gene mutations | TP53, ATM, NOTCH1, BIRC3, MYD88, SF3B1, FBXWY, POT1, CHD2, RPS15, IKZF3, ZNF292, ZMYM3, ARID1A, PRPN11, COBLL1, LPL, ZAP70 |
Non-coding RNA and others | MiR-15a, miR-16-1, miR-155, miR-29a, miR-29b, miR-34a, miR-125a, miR-155, miR-181b, I-tRF-GlyCCC |